Royalty Pharma Q2 Net Income Declines; Raises 2026 Guidance For Portfolio Receipts
· rttnews.com
Royalty Pharma plc (RPRX) reported that its second quarter net income attributable to Royalty Pharma declined to $18 million from $32 million, last year. Adjusted EBITDA increased to $736 million from $633 million.
Royalty Pharma plc (RPRX) reported that its second quarter net income attributable to Royalty Pharma declined to $18 million from $32 million, last year. Adjust...